KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Oral Semaglutide and Heart Failure Outcomes in Persons With Type 2 Diabetes: A Secondary Analysis of the SOUL Randomized Clinical Trial.

Rodica Pop-Busui, Søren Rasmussen, John E Deanfield, John B Buse, Nikolaus Marx, Sharon L Mulvagh, Silvio E Inzucchi, Johannes F E Mann, Scott S Emerson, Neil R Poulter, Mads D M Engelmann, G Kees Hovingh, Katrine Bayer Tanggaard, Andreas L Birkenfeld, Kim A Connelly, Martin Haluzik, Matthew A Cavender, Monika Kellerer, Pardeep S Jhund, Søren Gregersen, Olav Wendelboe Nielsen, Carolyn S P Lam, Darren K McGuire, SOUL Study Group

JAMA Intern Med 186(4) 426-436

PMID41627802
PMCIDPMC12865694
DOI10.1001/jamainternmed.2025.7774
发表日期2026-02-02
入排依据:未发现恶性肿瘤人群证据。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:Figure 1.:森林图/亚组分析图;Figure 2.:森林图/亚组分析图;Figure 3.:森林图/亚组分析图。
摘要

摘要

IMPORTANCE: Heart failure (HF) is a common complication of type 2 diabetes (T2D). Oral semaglutide reduced the risk of major adverse cardiovascular (CV) events (MACE; comprising CV death, nonfatal myocardial infarction, or nonfatal stroke) in people with T2D in the SOUL trial, but the impact on HF outcomes in these participants is unknown. OBJECTIVE: To evaluate the effect of oral semaglutide on HF events, MACE, and safety among participants with or without HF at baseline. DESIGN, SETTING, AND PARTICIPANTS: This is a secondary analysis of the double-blind, placebo-controlled, event-driven, phase 3b SOUL randomized clinical trial, which was conducted at 444 centers in 33 countries. Participants were enrolled from June 17, 2019, to March 24, 2021, and had T2D and atherosclerotic CV disease and/or chronic kidney disease, stratified according to the presence or absence of HF history at baseline. Data were analyzed from December 2024 to August 2025. INTERVENTION: Once-daily oral semaglutide or placebo in addition to standard of care. MAIN OUTCOMES AND MEASURES: Prespecified composite HF outcome (time to first occurrence of HF hospitalization, urgent HF visit, or CV death). RESULTS: Overall, 9650 participants (median [IQR] age, 66.0 [61.0-72.0] years; 2790 [28.9%] female) were randomized, with a mean (SD) follow-up of 47.5 (10.9) months. Of these participants, 2229 (23.1%) had HF history (991 [10.3%] with preserved ejection fraction, 592 [6.1%] with reduced ejection fraction, and 646 [6.7%] with unknown subtype). For participants with HF at baseline, the hazard ratio (HR) for risk of the composite HF outcome with oral semaglutide vs placebo was 0.78 (95% CI, 0.63-0.96) and was 1.01 (95% CI, 0.84-1.20) in those without HF at baseline (P for interaction = .06). Among participants with HF, the HR was 0.59 (95% CI, 0.39-0.86) in those with preserved ejection fraction and 0.98 (95% CI, 0.70-1.38) in those with reduced ejection fraction. There was no heterogeneity in the risk reduction of MACE with oral semaglutide in participants with HF history (HR, 0.83; 95% CI, 0.68-1.01) or without HF history (HR, 0.86; 95% CI, 0.75-0.98) (P for interaction = .77). Serious adverse event occurrence among participants with HF was similar with oral semaglutide (594 [53.8%]) and placebo (642 [57.1%]). CONCLUSIONS AND RELEVANCE: In this secondary analysis of the SOUL randomized clinical trial, among individuals with T2D, atherosclerotic CV disease, and/or chronic kidney disease, a reduction of HF events was observed with use of oral semaglutide compared with placebo in those with a history of HF, without increasing the risk of serious adverse events. These data support the potential benefit of oral semaglutide in reducing HF events in people with T2D and HF. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03914326.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1.Time to First Composite Heart Failure (HF) Outcome by Treatment and Baseline HF Status and Subtype Data are from the in-trial full-analysis set. The HF composite outcome comprised HF events (HF hospitalization or urgent HF visit) or cardiovascular death. For 3 participants, HF at baseline could not be determined. Missing data were defined as data planned to be collected according to protocol but not present in the database. Hence, data that are absent in the database due to death or administrative censoring were not considered missing and, therefore, not imputed. The P for interaction across HF subtypes (HF with preserved ejection fraction [HFpEF], HF with reduced ejection fraction [HFrEF], and unknown) and no HF at baseline in all randomized participants was .06. HR indicates hazard ratio.
非 KM Figure
Figure 2.Time to First Composite Heart Failure (HF) Outcome in Subgroups Among Participants With HF at Baseline Data are from the in-trial period in participants with HF at baseline. The composite HF outcome consists of HF hospitalization, urgent HF visit, or cardiovascular (CV) death. Time from randomization to relevant end point was analyzed using a Cox proportional hazards model with treatment as a fixed factor. Participants without events of interest were censored at the end of their in-trial period. For the subgroup analyses, estimated hazard ratios (HRs) and corresponding 95% CIs were calculated using a Cox proportional hazards model with interaction between treatment group and subgroup as a fixed factor. P values are for the test of no interaction effect. Race and ethnicity data were self-reported by participants, including the other category. BMI indicates body mass index (calculated as weight in kilograms divided by height in meters squared); CRP, C-reactive protein; HbA 1c , glycated hemoglobin A 1c ; HFpEF, HF with preserved ejection fraction; HFrEF, HF with reduced ejection fraction; MI, myocardial infarction; MRA, mineralocorticoid receptor antagonist; SGLT2, sodium-glucose cotransporter 2.
非 KM Figure
Figure 3.Time to First Occurrence of Major Adverse Cardiovascular Event (MACE) by Treatment and Baseline Heart Failure (HF) Status Data are from the in-trial full-analysis set. The MACE composite outcome comprised cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke. For 3 participants, HF at baseline could not be determined. Missing data were defined as data planned to be collected according to protocol but not present in the database. Hence, data that are absent in the database due to death or administrative censoring were not considered missing and, therefore, not imputed. The P for interaction across HF subtypes (HF with preserved ejection fraction [HFpEF], HF with reduced ejection fraction [HFrEF], and unknown) and no HF at baseline in all randomized participants was .61. HR indicates hazard ratio.
非 KM Figure